{"id":"NCT01419197","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy","officialTitle":"A Phase III Randomized, Multicenter, Two Arm, Open-label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2-positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2013-02","completion":"2015-08","firstPosted":"2011-08-18","resultsPosted":"2014-05-05","lastUpdate":"2016-10-12"},"enrollment":602,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Trastuzumab emtansine","otherNames":["Kadcyla","T-DM1"]},{"type":"DRUG","name":"Treatment of physician's choice","otherNames":[]}],"arms":[{"label":"Trastuzumab emtansine","type":"EXPERIMENTAL"},{"label":"Treatment of physician's choice","type":"ACTIVE_COMPARATOR"}],"summary":"This randomized, multicenter, 2-arm, open-label study (TH3RESA) will evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) in comparison with treatment of the physician's choice in participants with metastatic or unresectable locally advanced/recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Eligible participants will be randomized to receive either trastuzumab emtansine 3.6 mg/kg intravenously every 21 days or treatment of the physician's choice. Participants continue to receive study treatment until disease progression or unacceptable toxicity occurs. This study is also known under Roche study protocol number BO25734.","primaryOutcome":{"measure":"Progression-free Survival","timeFrame":"Baseline to the clinical cut-off date of 11 Feb 2013 (up to 2 years)","effectByArm":[{"arm":"Trastuzumab Emtansine","deltaMin":6.2,"sd":null},{"arm":"Treatment of Physician's Choice","deltaMin":3.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":5},"locations":{"siteCount":184,"countries":["United States","Australia","Belgium","Brazil","Canada","Czechia","France","Germany","Hungary","India","Israel","Italy","Norway","Poland","Russia","Slovakia","South Korea","Spain","Sweden","Switzerland","Thailand","United Kingdom"]},"refs":{"pmids":["28733983","28526538","24793816"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":102,"n":403},"commonTop":["Nausea","Fatigue","Headache","Constipation","Asthenia"]}}